Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | GRM1 | Q13255 | 6/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | CTSV | O60911 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL950697 | 0.88 | CYP19A1 (0.52) | CYP19A1ATMGRM1POLBEPHX2 | |
| SCHEMBL14665410 | 0.88 | CYP19A1 (0.52) | CYP19A1ATMGRM1POLBEPHX2 | |
| SCHEMBL2995532 | 0.86 | CYP19A1 (0.56) | CYP19A1ATMGRM1POLBEPHX2 | |
| SCHEMBL4657482 | 0.86 | CYP19A1 (0.56) | CYP19A1ATMGRM1POLBEPHX2 | |
| SCHEMBL28223461 | 0.83 | CYP19A1 (0.54) | CYP19A1ATMGRM1POLBEPHX2 | |
| SCHEMBL26968959 | 0.83 | CYP19A1 (0.54) | CYP19A1ATMGRM1POLBEPHX2 | |
| SCHEMBL8861069 | 0.83 | CYP19A1 (0.54) | CYP19A1ATMGRM1POLBEPHX2 | |
| SCHEMBL2820777 | 0.83 | CYP19A1 (0.54) | CYP19A1ATMGRM1POLBEPHX2 | |
| SCHEMBL8861066 | 0.83 | CYP19A1 (0.54) | CYP19A1ATMGRM1POLBEPHX2 | |
| SCHEMBL2625630 | 0.81 | ATM (0.54) | CYP19A1ATMGRM1POLBEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120148954-A1 | N-ACYL-B-LACTAM DERIVATIVE, MACROMOLECULAR COMPOUND, AND PHOTORESIST COMPOSITION | KURARAY CO., LTD. (JP) | 2012-06-14 | — | — | US | disclosed |
| CN-1239310-C | Co-injection-drawing blow mouled container | KURARAY CO (JP) | 2006-02-01 | — | — | CN | disclosed |
| CN-1438108-A | Co-injection-drawing blow mouled container | KURARAY CO (JP) | 2003-08-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120148954-A1 | N-ACYL-B-LACTAM DERIVATIVE, MACROMOLECULAR COMPOUND, AND PHOTORESIST COMPOSITION | COASY, ARCN1, CLTB | CYP19A1 627/4885ATM 871/4885GRM1 1966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.